AustinPx™

AustinPx^TM, Pharmaceutics and Manufacturing, was founded in 2007 (as DisperSol Technologies) and is a fee-for-service CDMO offering preclinical through Phase II formulation and process development and GMP manufacturing of oral dosage forms.  AustinPx^TM specializes in bioavailability enhancement, speed to clinic and market development strategies, and dose form development.

AustinPx^TM has a data-driven and agnostic approach which means their formulation and strategy for each drug is based on the unique and physiochemistry of that compound.  For poorly soluble compounds, AustinPx^TM has one of the most powerful tools available in KinetiSol®.  KinetiSol®, a next generation technology for rendering active pharmaceutical ingredients amorphous, evolved from a research collaboration with the College of Pharmacy at The University of Texas at Austin.  KinetiSol is an innovative technology for the production of drug-polymer composite systems most notably for solubility/bioavailability enhancement of poorly water-soluble compounds.

The cGMP facility at AustinPx^TM can supply oral formulations using KinetiSol® and other production technologies for preclinical testing, GLP toxicology studies, and Phase I/II clinical studies.  AustinPx^TM can also provide Phase III and commercial supply of amorphous drug product intermediate (DPI) using its KinetiSol® technology.